This week's roundup includes CEO appointments by various companies including Mustang Bio, GammaDelta and Modus Therapeutics and other high-level appointments by Bayer, Renova, Metrion and Poxel.
Bayer AG has appointed Bhavesh Ashar senior vice president and head of oncology for the company's US pharmaceutical division. Ashar was vice president and general manager of US oncology at Sanofi, where he spent over 14 years holding positions of increasing responsibility in sales and marketing. Before Sanofi, he was an engagement manager with McKinsey & Company.
Mustang Bio Inc. has named Manuel Litchman president, CEO and a member of the company’s board of directors. Michael...
The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.
<p>Executive Summary </p> <br> <p>Other recent moves in the industry include changes at the top at Adocia, CSL and Entrada Therapeutics.</p>
Starboard Value has reportedly bought a $1bn stake in Pfizer with an ambition to turn the big pharma around. But growth, not cost cuts, are Pfizer’s challenge.
<p>Executive Summary </p> <br> <p>Other recent moves in the industry include changes at the top at Adocia, CSL and Entrada Therapeutics.</p>
<p>Executive Summary </p> <br> <p>Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements</p>
